JP2011519359A - アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh - Google Patents

アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh Download PDF

Info

Publication number
JP2011519359A
JP2011519359A JP2011504527A JP2011504527A JP2011519359A JP 2011519359 A JP2011519359 A JP 2011519359A JP 2011504527 A JP2011504527 A JP 2011504527A JP 2011504527 A JP2011504527 A JP 2011504527A JP 2011519359 A JP2011519359 A JP 2011519359A
Authority
JP
Japan
Prior art keywords
sialylation
fsh
rfsh
recombinant fsh
sialic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011504527A
Other languages
English (en)
Japanese (ja)
Inventor
コッティンガム,イアン
プラクシン,ダニエル
ホワイト,リチャード,ボイド
Original Assignee
フェリング インターナショナル センター エス.アー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011519359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by フェリング インターナショナル センター エス.アー. filed Critical フェリング インターナショナル センター エス.アー.
Publication of JP2011519359A publication Critical patent/JP2011519359A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011504527A 2008-04-16 2009-04-16 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh Pending JP2011519359A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014262056A Division JP2015120696A (ja) 2008-04-16 2014-12-25 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh

Publications (1)

Publication Number Publication Date
JP2011519359A true JP2011519359A (ja) 2011-07-07

Family

ID=39717519

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2011504527A Pending JP2011519359A (ja) 2008-04-16 2009-04-16 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh
JP2014262056A Pending JP2015120696A (ja) 2008-04-16 2014-12-25 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh
JP2016198588A Active JP6486310B2 (ja) 2008-04-16 2016-10-07 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh
JP2017148823A Active JP6762916B2 (ja) 2008-04-16 2017-08-01 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh
JP2019194476A Active JP7316905B2 (ja) 2008-04-16 2019-10-25 アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh
JP2021175403A Pending JP2022031652A (ja) 2008-04-16 2021-10-27 アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh
JP2023215339A Pending JP2024038000A (ja) 2008-04-16 2023-12-21 アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014262056A Pending JP2015120696A (ja) 2008-04-16 2014-12-25 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh
JP2016198588A Active JP6486310B2 (ja) 2008-04-16 2016-10-07 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh
JP2017148823A Active JP6762916B2 (ja) 2008-04-16 2017-08-01 アルファ2,3−およびアルファ2,6−シアリル化を含む組換えfsh
JP2019194476A Active JP7316905B2 (ja) 2008-04-16 2019-10-25 アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh
JP2021175403A Pending JP2022031652A (ja) 2008-04-16 2021-10-27 アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh
JP2023215339A Pending JP2024038000A (ja) 2008-04-16 2023-12-21 アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh

Country Status (29)

Country Link
US (7) US8951967B2 (cg-RX-API-DMAC7.html)
EP (7) EP3098234B1 (cg-RX-API-DMAC7.html)
JP (7) JP2011519359A (cg-RX-API-DMAC7.html)
KR (5) KR102108377B1 (cg-RX-API-DMAC7.html)
CN (3) CN105906703A (cg-RX-API-DMAC7.html)
AR (1) AR071479A1 (cg-RX-API-DMAC7.html)
AU (5) AU2009237479B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910461B8 (cg-RX-API-DMAC7.html)
CA (1) CA2725257A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115413T1 (cg-RX-API-DMAC7.html)
DK (6) DK3098234T3 (cg-RX-API-DMAC7.html)
ES (5) ES2989729T3 (cg-RX-API-DMAC7.html)
FI (4) FI4015527T3 (cg-RX-API-DMAC7.html)
FR (3) FR17C1020I2 (cg-RX-API-DMAC7.html)
HR (5) HRP20241187T1 (cg-RX-API-DMAC7.html)
HU (9) HUE033830T2 (cg-RX-API-DMAC7.html)
IL (2) IL208538A (cg-RX-API-DMAC7.html)
LT (8) LT3045471T (cg-RX-API-DMAC7.html)
MX (3) MX348622B (cg-RX-API-DMAC7.html)
NO (4) NO2017025I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ588381A (cg-RX-API-DMAC7.html)
PL (6) PL2808340T3 (cg-RX-API-DMAC7.html)
PT (6) PT3144318T (cg-RX-API-DMAC7.html)
RU (3) RU2682270C2 (cg-RX-API-DMAC7.html)
SA (1) SA109300228B1 (cg-RX-API-DMAC7.html)
SI (6) SI2808340T1 (cg-RX-API-DMAC7.html)
TW (1) TWI488640B (cg-RX-API-DMAC7.html)
WO (1) WO2009127826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007373B (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014522871A (ja) * 2011-08-08 2014-09-08 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JPWO2013161958A1 (ja) * 2012-04-27 2015-12-24 Jcrファーマ株式会社 新規な発現ベクター
JP2019509728A (ja) * 2016-02-15 2019-04-11 ツェヴェック ファーマシューティカルズ ゲーエムベーハー ジアンテナ型n−グリカンを有する組み換え糖タンパク質を産生する細胞株、それを使用する方法、及び組み換え糖タンパク質
JP2020515254A (ja) * 2017-03-29 2020-05-28 ツェヴェック ファーマシューティカルズ ゲーエムベーハー アンテナ型フコシル化が減少された組み換え糖タンパク質

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
WO2019211153A1 (en) 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
CN118922201A (zh) 2022-04-01 2024-11-08 辉凌公司 治疗不育症的混合方案
KR20250016113A (ko) 2022-05-26 2025-02-03 훼링 비.브이. 남성 불임 치료를 위한 조성물 및 방법
MA71382A (fr) 2022-07-08 2025-04-30 Ferring B.V. Compositions et procédés d'insémination intra-utérine (iiu)
KR20260041113A (ko) 2023-07-20 2026-03-26 훼링 비.브이. 서방형의 약물-로딩된 마이크로입자

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011665A1 (en) * 1997-09-01 1999-03-11 Kirin Brewery Company, Limited Human thrombopoietin produced by established human cell lines, process for producing the same, and medicinal compositions containing the same
JP2005515974A (ja) * 2001-10-22 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 卵胞形成のためのゴナドドロピン
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド GlycoPEG化卵胞刺激ホルモン

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
CA2372714A1 (en) 1999-05-07 2000-11-16 Stephen Franks The use of luteinizing hormone in the induction of pauci-or unifolliculogenesis
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
EA008220B1 (ru) 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ATE476666T1 (de) 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011665A1 (en) * 1997-09-01 1999-03-11 Kirin Brewery Company, Limited Human thrombopoietin produced by established human cell lines, process for producing the same, and medicinal compositions containing the same
JP2005515974A (ja) * 2001-10-22 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 卵胞形成のためのゴナドドロピン
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド GlycoPEG化卵胞刺激ホルモン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FERTILITY AND STERILITY,2004年 8月,V82 NO.2,P348-357, JPN6015009482, ISSN: 0003025449 *
FLACK M R: "INCREASED BIOLOGICAL ACTIVITY DUE TO BASIC ISOFORMS IN RECOMBINANT HUMAN 以下備考", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. V79 NO.3, JPN5011001071, September 1994 (1994-09-01), pages 756 - 760, ISSN: 0002700831 *
HUMAN REPRODUCTION, 2000, 15(9), PP.1898-1902, JPN6013060593, ISSN: 0002700832 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291708B2 (en) 2011-08-08 2022-04-05 Ferring B.V. Human-derived recombinant FSH for controlled ovarian stimulation
JP7309660B2 (ja) 2011-08-08 2023-07-18 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
US9694052B2 (en) 2011-08-08 2017-07-04 Ferring B.V. FSH composition and methods for controlled ovarian stimulation
JP2017141253A (ja) * 2011-08-08 2017-08-17 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JP7844394B2 (ja) 2011-08-08 2026-04-13 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
US10624953B2 (en) 2011-08-08 2020-04-21 Ferring B.V. Human-derived recombinant FSH for controlled ovarian stimulation
JP2020147600A (ja) * 2011-08-08 2020-09-17 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JP2023134561A (ja) * 2011-08-08 2023-09-27 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JP2014522871A (ja) * 2011-08-08 2014-09-08 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JPWO2013161958A1 (ja) * 2012-04-27 2015-12-24 Jcrファーマ株式会社 新規な発現ベクター
JP2019509728A (ja) * 2016-02-15 2019-04-11 ツェヴェック ファーマシューティカルズ ゲーエムベーハー ジアンテナ型n−グリカンを有する組み換え糖タンパク質を産生する細胞株、それを使用する方法、及び組み換え糖タンパク質
JP7110104B2 (ja) 2016-02-15 2022-08-01 ツェヴェック ファーマシューティカルズ ゲーエムベーハー ジアンテナ型n-グリカンを有する組み換え糖タンパク質を産生する細胞株、それを使用する方法、及び組み換え糖タンパク質
US11193156B2 (en) 2017-03-29 2021-12-07 Cevec Pharmaceutical GmbH Recombinant glycoproteins with reduced antennary fucosylation
JP2020515254A (ja) * 2017-03-29 2020-05-28 ツェヴェック ファーマシューティカルズ ゲーエムベーハー アンテナ型フコシル化が減少された組み換え糖タンパク質

Also Published As

Publication number Publication date
EP2268666A1 (en) 2011-01-05
SI3045471T1 (sl) 2017-07-31
KR20110005863A (ko) 2011-01-19
LT2808340T (lt) 2016-11-10
HRP20170958T1 (hr) 2017-09-22
PL3098234T3 (pl) 2025-01-07
HUS2500029I1 (hu) 2025-07-28
FI3098234T3 (fi) 2024-10-31
EP3045471B1 (en) 2017-03-29
LT3098234T (lt) 2024-09-10
RU2745557C1 (ru) 2021-03-29
US20110105398A1 (en) 2011-05-05
JP6762916B2 (ja) 2020-09-30
CA2725257A1 (en) 2009-10-22
DK4015527T3 (da) 2025-04-14
SI3144318T1 (sl) 2020-12-31
ES2629392T3 (es) 2017-08-09
SI4015527T1 (sl) 2025-05-30
AU2017204258A1 (en) 2017-07-20
US9546204B2 (en) 2017-01-17
FR25C1025I1 (fr) 2025-09-19
EP3098234B1 (en) 2024-07-31
NO2025006I1 (no) 2025-01-16
HUE068565T2 (hu) 2025-01-28
US11952407B2 (en) 2024-04-09
AU2014203277C1 (en) 2017-07-27
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
CY1115413T1 (el) 2017-01-04
NO2017025I1 (no) 2017-06-06
JP2017060476A (ja) 2017-03-30
HUS1700025I1 (hu) 2017-06-28
AU2014203277B2 (en) 2017-04-06
WO2009127826A1 (en) 2009-10-22
PT4015527T (pt) 2025-04-10
NO2025032I1 (no) 2025-07-14
EP3144318A1 (en) 2017-03-22
RU2745557C3 (ru) 2021-12-10
SI2808340T1 (sl) 2016-12-30
SI2268666T1 (sl) 2014-07-31
PT2808340T (pt) 2016-11-21
RU2537268C2 (ru) 2014-12-27
BRPI0910461A8 (pt) 2018-10-16
KR101622944B1 (ko) 2016-05-23
PL3045471T3 (pl) 2017-10-31
EP3045471A1 (en) 2016-07-20
LT3045471T (lt) 2017-07-10
US20150065695A1 (en) 2015-03-05
CN105906703A (zh) 2016-08-31
ES3023526T3 (en) 2025-06-02
PL2268666T3 (pl) 2014-08-29
FR17C1020I1 (cg-RX-API-DMAC7.html) 2020-04-10
HUE033830T2 (en) 2018-01-29
US20180079794A1 (en) 2018-03-22
HUE030652T2 (en) 2017-05-29
DK3098234T3 (da) 2024-10-21
JP6486310B2 (ja) 2019-03-20
US20240327487A1 (en) 2024-10-03
PT3045471T (pt) 2017-06-14
KR102108377B1 (ko) 2020-05-08
BRPI0910461A2 (pt) 2018-03-27
HUS2500008I1 (hu) 2025-02-28
KR20180095140A (ko) 2018-08-24
PT3144318T (pt) 2020-11-04
US9771407B2 (en) 2017-09-26
AU2017225020A1 (en) 2017-09-28
EP4015527B1 (en) 2025-01-22
FIC20250025I1 (fi) 2025-07-11
EP3098234A1 (en) 2016-11-30
JP7316905B2 (ja) 2023-07-28
AU2017225020B2 (en) 2019-11-14
LTPA2017018I1 (lt) 2017-06-26
ZA201007373B (en) 2011-06-29
FR17C1020I2 (fr) 2020-04-10
FIC20250003I1 (fi) 2025-01-15
US20210332099A1 (en) 2021-10-28
US10995128B2 (en) 2021-05-04
RU2014141994A (ru) 2016-05-10
JP2024038000A (ja) 2024-03-19
SI3098234T1 (sl) 2024-10-30
US8951967B2 (en) 2015-02-10
PT3098234T (pt) 2024-10-21
TW200948378A (en) 2009-12-01
RU2010141908A (ru) 2012-05-27
IL208538A (en) 2014-03-31
KR20160056960A (ko) 2016-05-20
AR071479A1 (es) 2010-06-23
HRP20241187T1 (hr) 2024-12-06
MX348622B (es) 2017-06-22
HUS1700036I1 (hu) 2017-10-30
JP2015120696A (ja) 2015-07-02
DK2268666T3 (da) 2014-05-12
TWI488640B (zh) 2015-06-21
BRPI0910461B8 (pt) 2021-05-25
CN102066414A (zh) 2011-05-18
US12516094B2 (en) 2026-01-06
FR25C1003I1 (fr) 2025-02-28
RU2014141994A3 (cg-RX-API-DMAC7.html) 2018-05-28
ES2468318T3 (es) 2014-06-16
AU2009237479A1 (en) 2009-10-22
US20160347811A1 (en) 2016-12-01
AU2017204259B2 (en) 2017-08-17
IL230571A (en) 2015-11-30
BRPI0910461B1 (pt) 2021-02-23
JP2020040956A (ja) 2020-03-19
HUE071059T2 (hu) 2025-07-28
KR20190092608A (ko) 2019-08-07
ES2989729T3 (es) 2024-11-27
DK2808340T3 (en) 2016-12-05
AU2017204259A1 (en) 2017-07-20
NO2017050I1 (no) 2017-09-28
LT4015527T (lt) 2025-04-10
EP2808340A1 (en) 2014-12-03
IL208538A0 (en) 2010-12-30
PL2808340T3 (pl) 2017-02-28
PL3144318T3 (pl) 2021-02-08
HRP20161520T1 (hr) 2016-12-30
RU2682270C2 (ru) 2019-03-18
HUE030652T4 (en) 2017-09-28
HRP20250313T1 (hr) 2025-05-09
HK1146284A1 (en) 2011-05-20
LTPA2017029I1 (lt) 2017-10-10
EP2268666B1 (en) 2014-03-12
LTPA2025505I1 (cg-RX-API-DMAC7.html) 2025-02-10
AU2017204258B2 (en) 2017-08-17
HK1199039A1 (en) 2015-06-19
KR20170110741A (ko) 2017-10-11
JP2018021037A (ja) 2018-02-08
DK3144318T3 (da) 2020-12-07
JP2022031652A (ja) 2022-02-22
US20260217782A1 (en) 2026-07-30
AU2009237479B2 (en) 2014-05-15
CN105906702A (zh) 2016-08-31
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
AU2014203277A1 (en) 2014-07-24
SA109300228B1 (ar) 2014-04-08
EP3144318B1 (en) 2020-09-23
NZ588381A (en) 2012-05-25
MX355457B (es) 2018-04-19
PT2268666E (pt) 2014-06-25
HUS1700024I1 (hu) 2017-06-28
DK3045471T3 (en) 2017-06-26
EP2808340B1 (en) 2016-08-17
FI4015527T3 (fi) 2025-04-29
LTPA2025525I1 (cg-RX-API-DMAC7.html) 2025-07-25
EP4015527A1 (en) 2022-06-22
EP2722339A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
JP7316905B2 (ja) アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh
HK40068781B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227049B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1146284B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202